A new nasal-delivered nanotherapy shows promise against aggressive glioblastoma tumors. By activating the STING immune pathway using gold-core spherical nucleic acids, researchers were able to reach ...
A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute has shown that a single injection of an ...
CLEVELAND, Ohio — The Ohio State University’s James Cancer Hospital has treated the world’s first brain cancer patient to receive a new radiation technology that attacks tumors from within, the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The highest enrolling ...
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help ...
NovoCure remains a 'Sell' as TTFields' utility is largely capped at glioblastoma, with limited expansion potential. 2025 revenue grew 8% to $655 million, but new indications like NSCLC and ...
ImmunityBio, Inc. ( NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, today announced updated Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results